Heptares at Upcoming Diabetes and Neuroscience Partnering and Investment Conferences
LONDON, April 16, 2014 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be attending two upcoming industry partnering and investment conferences.
Mr Grau will attend the 9th Annual Neurotech Investing & Partnering Conference in Boston, MA, USA (23-24 April 2014) at which he will participate in a panel discussion entitled Next Generation Psychiatry at 2.30pm EST on Thursday 24 April.
Mr Grau will also attend the Diabetes Summit 2014 in Cambridge, MA, USA (23-25 April 2014), where he will participate in two panel discussions on Friday 25 April: Diabetes Partnering & Deal-making - Current Trends & Recent Deals at 10.45am EST and Finding the Middle Ground in Big Pharma and Biotech Partnerships at 1.15pm EST.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR is a registered trademark in the EU and Japan.
SOURCE Heptares Therapeutics